Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report

Journal of Psychopharmacology

Volumn 25, Issue 1, 2011, Pages 121-130

  Crippa, José Alexandre S ^a,b   Nogueira Derenusson, Guilherme ^a,b   Borduqui Ferrari, Thiago ^a,b   Wichert Ana, Lauro ^a   Duran, Fábio L S ^a   Martin Santos, Rocio ^b,c   Vinícius Simões, Marcus ^a   Bhattacharyya, Sagnik ^c   Fusar Poli, Paolo ^c   Atakan, Zerrin ^c   Santos Filho, Alaor ^a,b   Freitas Ferrari, Maria Cecília ^a,b   McGuire, Philip K ^b,c   Zuardi, Antonio Waldo ^a,b   Busatto, Geraldo F ^a   Hallak, Jaime Eduardo Cecílio ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NCT Translational Medicine   (Brazil)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cannabidiol; CBD; regional cerebral blood flow; social anxiety; SPECT

Indexed keywords

CANNABIDIOL; CYSTEINE ETHYL ESTER TC 99M; PLACEBO;

ADULT; ARTICLE; BRAIN BLOOD FLOW; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; HIPPOCAMPUS; HUMAN; MALE; NEUROIMAGING; PRIORITY JOURNAL; RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL PHOBIA; SUBICULUM; TEMPORAL GYRUS;

ADULT; ANTI-ANXIETY AGENTS; ANXIETY; ANXIETY DISORDERS; BRAIN; CANNABIDIOL; CEREBROVASCULAR CIRCULATION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; REGIONAL BLOOD FLOW; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 78650625479     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110379283     Document Type: Article

References (112)

1. Afifi AK and Bergman RA (1998) Functional Neuroanatomy: Text and Atlas. New York: McGraw-Hill.
2. Agurell S., Carlsson S., Lindgren JE, Ohlsson A., Gillespie H. and Hollister L. (1981) Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 37: 1090-1092.
3. Agurell S., Halldin M., Lindgren JE, Ohlsson A., Widman M., Gillespie H., et al. (1986) Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38: 21-43.
4. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde DE, Brandi I., et al. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845-852.
5. Blanco C., Antia SX and Liebowitz MR (2002) Pharmacotherapy of social anxiety disorder. Biol Psychiatry 51: 109-120.
6. Bond A. and Lader M. (1974) The use of analogues scale in rating subjective feelings. Br J Med Psychol 47: 211-218.
7. Borgwardt SJ, Allen P., Bhattacharyya S., Fusar-Poli P., Crippa JA, Seal ML, et al. (2008) Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 64: 966-973.
8. Boshuisen ML, Ter Horst GJ, Paans AM, Reinders AA and den Boer JA (2002) rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. Biol Psychiatry 52: 126-135.
9. Bremner JD, Narayan M., Staib LH, Southwick SM, McGlashan T. and Charney DS (1999) Neural correlates of memories of childhood sexual abuse in women with and without posttraumatic stress disorder. Am J Psychiatry 156: 1787-1795.
10. Brett M., Johnsrude IS and Owen AM (2002) The problem of functional localization in the human brain. Nat Rev Neurosci 3: 243-249.
11. Buckner JD, Bonn-Miller MO, Zvolensky MJ and Schmidt NB (2007) Marijuana use motives and social anxiety among marijuana-using young adults. Addict Behav 32: 2238-2252.
12. Buckner JD, Schmidt NB, Bobadilla L. and Taylor J. (2006) Social anxiety and problematic cannabis use: evaluating the moderating role of stress reactivity and perceived coping. Behav Res Ther 44: 1007-1015.
13. Buckner JD, Schmidt NB, Lang AR, Small JW, Schlauch RC and Lewinsohn PM (2008) Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. J Psychiatr Res 42: 230-239.
14. Bystritsky A., Pontillo D., Powers M., Sabb FW, Craske MG and Bookheimer SY (2001) Functional MRI changes during panic anticipation and imagery exposure. Neuroreport 12: 3953-3957.
15. Campos AC and Guimarães FS (2008) Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) 199: 223-230.
16. Cannistraro PA and Rauch SL (2003) Neural circuitry of anxiety: evidence from structural and functional neuroimaging studies. Psychopharmacol Bull 37: 8-25.
17. Carey PD, Warwick J., Niehaus DJ, van der Linden G., van Heerden BB, Harvey BH, et al. (2004) Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BMC Psychiatry 4: 30.
18. Carlini EA, Masur J. and Magalhães Ccpb (1979) Possível efeito hipnótico do cannabidiol no ser humano. Estudo preliminar. Ciência e Cultura 31: 315-322.
19. Connor KM, Davidson JR, Churchill LE, Sherwood A., Foa E. and Weisler RH (2000) Psychometric properties of Social Phobia Inventory (SPIN). Br J Psychiatry 176: 379-386.
20. Consroe P., Laguna J., Allender J., Snider S., Stern L., Sandyk R., et al. (1991) Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 40: 701-708.
21. Crippa JA, de Lima Osório F., Del-Bem CM, Filho AS, da Silva Freitas MC and Loureiro SR (2008) Comparability between telephone and face-to-face structured clinical interview for DSM-IV in assessing social anxiety disorder. Perspect Psychiatr Care 44: 241-247.
22. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L., Guarnier R., Ferrari L., et al. (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29: 417-426.
23. Crippa JAS, Zuardi AW and Hallak JEC (2010) Therapeutical use of the cannabinoids in psychiatry. Rev Bras Psiquiatr 32 (Suppl I). S56 - S66.
24. Crippa JA, Zuardi AW, Martín-Santos R., Bhattacharyya S., Atakan Z., McGuire P., et al. (2009) Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 24: 515-523.
25. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C., Gagliardi R., et al. (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21: 175-185.
26. Davidson JR (2003) Pharmacotherapy of social phobia. Acta Psychiatr Scand 417: 65-71.
27. Davidson JR, Potts NL, Richichi EA, Ford SM, Krishnan KR, Smith RD, et al. (1991) The Brief Social Phobia Scale. J Clin Psychiatry 52: 48-51.
28. De Lima Osório F., Crippa JA and Loureiro SR (2007) A study of the discriminative validity of a screening tool (MINI-SPIN) for social anxiety disorder applied to Brazilian university students. Eur Psychiatry 22: 239-243.
29. Di Piero V., Ferracuti S., Sabatini U., Tombari D., Di Legge S., Pantano P., et al. (2001) Diazepam effects on the cerebral responses to tonic pain: a SPET study. Psychopharmacology (Berl) 158: 252-258.
30. Doronbekov TK, Tokunaga H. and Ikejiri Y. (2005) Neural basis of fear conditioning induced by video clip: positron emission tomography study. Psychiatry Clin Neurosci 59: 155-162.
31. Eser D., Leicht G., Lutz J., Wenninger S., Kirsch V., Schüle C., et al. (2009) Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers. Hum Brain Mapp 30: 511-522.
32. Etkin A. and Wager TD (2007) Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 164: 1476-1488.
33. Ferrari MC, Busatto GF, McGuire PK and Crippa JA (2008) Structural magnetic resonance imaging in anxiety disorders: an update of research findings. Rev Bras Psiquiatr 30: 251-264.
34. Fischer H., Wik G. and Fredrikson M. (1996) Functional neuroanatomy of robbery re-experience: affective memories studied with PET. Neuroreport 7: 2081-2086.
35. Freitas-Ferrari MC, Hallak JE, Trzesniak C., Filho AS, Machado-de-Sousa JP, Chagas MH, et al. (2010) Neuroimaging in social anxiety disorder: A systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 34: 565-580.
36. Freund TF, Katona I. and Piomelli D. (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83: 1017-1066. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD and Frackowiak RSJ (1995) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2: 189-210.
37. Friston KJ, Holmes A., Poline JB, Price CJ and Frith CD (1996) Detecting activations in PET and fMRI: levels of inference and power. Neuroimage 4: 223-235.
38. Furmark T., Appel L., Michelgård A., Wahlstedt K., Ahs F., Zancan S., et al. (2005) Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58: 132-142.
39. Fusar-Poli P., Crippa JA, Bhattacharyya S., Borgwardt SJ, Allen P., Martin-Santos R., et al. (2009) Distinct effects of {delta}9- tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66: 95-105.
40. Gaetani S., Cuomo V. and Piomelli D. (2003) Anandamide hydrolysis: a new target for anti-anxiety drugs ? Trends Mol Med 9: 474-478.
41. Giordani B., Boivin MJ, Berent S., Betley AT, Koeppe RA, Rothley JM, et al. (1990) Anxiety and cerebral cortical metabolism in normal persons. Psychiatry Res 35: 49-60.
42. Grey SJ, Price G. and Mathews A. (2000) Reduction of anxiety during MR imaging: a controlled trial. Magn Reson Imaging 18: 351-355.
43. Guimarães FS, Chiaretti TM, Graeff FG and Zuardi AW (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 100: 558-559.
44. Guimarães FS, Kohem CL, Gus G., Fillmann HS, de-Vecino MC, dePaoli CL, et al. (1989) A simple simulated public speaking test for evaluating anxiolytic drugs. Braz J Med Biol Res 22: 1083-1089.
45. Gur RC, Gur RE, Resnick SM, Skolnick BE, Alavi A. and Reivich M. (1987) The effect of anxiety on cortical cerebral blood flow and metabolism. J Cereb Blood Flow Metab 7: 173-177.
46. Hallak JEC, Crippa JAS, Quevedo J., Roesler R., Schröder N., Nardi AE, et al. (2010) National Science and Technology Institute for Translational Medicine (INCT-TM): advancing the field of translational medicine and mental health. Rev Bras Psiquiatr 32: 83-90.
47. Hoehn-Saric R., Lee JS, McLeod DR and Wong DF (2005) Effect of worry on regional cerebral blood flow in nonanxious subjects. Psychiatry Res 140: 259-269.
48. Hou C., Liu J., Wang K., Li L., Liang M., He Z., et al. (2007) Brain responses to symptom provocation and trauma-related short-term memory recall in coal mining accident survivors with acute severe PTSD. Brain Res 1144: 165-174.
49. Kilts CD, Kelsey JE, Knight B., Ely TD, Bowman FD, Gross RE, et al. (2006) The neural correlates of social anxiety disorder and response to pharmacotherapy. Neuropsychopharmacology 31: 2243-2253.
50. Liotti M., Mayberg HS, Brannan SK, McGinnis S., Jerabek P. and Fox PT (2000) Differential limbic-cortical correlates of sadness and anxiety in healthy subjects: implications for affective disorders. Biol Psychiatry 48: 30-42.
51. McGuire PK, Bench CJ, Frith CD, Marks IM, Frackowiak RS and Dolan RJ (1994) Functional anatomy of obsessive-compulsive phenomena. Br J Psychiatry 164: 459-468.
52. MacLean PD (1993) Perspectives on cingulate cortex in the limbic system. In: Vogt BA and Gabriel M (eds) Neurobiology of Cingulate Cortex and Limbic Thalamus. Basel, Boston: Birkhäuser, 1-15.
53. Maddock RJ, Buonocore MH, Kile SJ and Garrett AS (2003) Brain regions showing increased activation by threat-related words in panic disorder. Neuroreport 14: 325-328.
54. Maddock RJ (1999) The retrosplenial cortex and emotion: new insights from functional neuroimaging of the human brain. Trends Neurosci 22: 310-316.
55. Malizia AL (1999) What do brain imaging studies tell us about anxiety disorders ? J Psychopharmacol 13: 372-378.
56. Maltby N., Tolin DF, Worhunsky P., O'Keefe TM and Kiehl KA (2005) Dysfunctional action monitoring hyperactivates frontalstriatal circuits in obsessive-compulsive disorder: an event-related fMRI study. Neuroimage 24: 495-503.
57. Marsicano G., Wotjak CT, Azad SC, Bisogno T., Rammes G., Cascio MG, et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530-534.
58. Mathew RJ, Wilson WH, Chiu NY, Turkington TG, Degrado TR and Coleman RE (1999) Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatr Scand 100: 67-75.
59. Mathew RJ, Wilson WH, Humphreys DF, Lowe JV and Wiethe KE (1992) Regional cerebral blood flow after marijuana smoking. J Cereb Blood Flow Metab 12: 750-758.
60. Mazziotta JC, Toga AW, Evans A., Fox P. and Lancaster J. (1995) A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). Neuroimage 2: 89-101.
61. McLellan AT, Luborsky L., O'Brien CP and Woody GE (1980) An improved diagnostic instrument for substance abuse patients: the Addiction Severity Index. J Nerv Ment Dis 168: 26-33.
62. Mechoulam R. and Hanus L. (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 121: 35-43.
63. Moreira FA, Aguiar DC and Guimarães FS (2006) Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 30: 1466-1471.
64. Musty RE, Conti LH and Mechoulam R. (1984) Anxiolytic properties of cannabidiol. In: Harvey DJ, (eds) Marihuana '84. Proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press Limited, 713-719.
65. Norris H. (1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 10: 181-191.
66. Onaivi ES, Green MR and Martin BR (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253: 1002-1009.
67. Osório FL, Crippa JAS and Loureiro SR (2006) Cross-cultural validation of the Brief Social Phobia Scale for use in Portuguese and the development of a structured interview guide. Rev Bras Psiquiatr 28: 212-217.
68. Osório F., de L., Crippa JA and Loureiro SR (2009) Cross-cultural validation of the Brazilian Portuguese version of the Social Phobia Inventory (SPIN). study of the items and internal consistency. Rev Bras Psiquiatr 31: 25-29.
69. Osório FL, Crippa JA and Loureiro SR (2010) Study of the psychometric qualities of the Brief Social Phobia Scale (BSPS) in Brazilian university students. Eur Psychiatry 25: 178-188.
70. Osuch EA, Benson B., Geraci M., Podell D., Herscovitch P., McCann UD, et al. (2001) Regional cerebral blood flow correlated with flashback intensity in patients with posttraumatic stress disorder. Biol Psychiatry 50: 246-253.
71. Paquette V., Lévesque J., Mensour B., Leroux JM, Beaudoin G., Bourgouin P., et al. (2003) ''Change the mind and you change the brain'': effects of cognitive-behavioral therapy on the neural correlates of spider phobia. Neuroimage 18: 401-409.
72. Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
73. Pickens JT (1981) Sedative activity of cannabis in relation to its Δ9-tetrahydrocannabinol and cannabidiol content. Br J Pharmac 72: 649-656.
74. Prasko J., Horácek J., Zálesky R., Kopecek M., Novák T., Pasková B., et al. (2004) The change of regional brain metabolism (18FDG PET) in panic disorder during the treatment with cognitive behavioral therapy or antidepressants. Neuro Endocrinol Lett 25: 340-348.
75. Rakhshan F., Day TA, Blakely RD and Barker EL (2000) Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J Pharmacol Exp Ther 292: 960-967.
76. Rauch SL, Dougherty DD, Cosgrove GR, Cassem EH, Alpert NM, Price BH, et al. (2001) Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for obsessive compulsive disorder. Biol Psychiatry 50: 659-667.
77. Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ and Jenike MA (2002) Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 27: 782-791.
78. Reichenberg A. and Harvey PD (2007) Neuropsychological impairments in schizophrenia: Integration of performance-based and brain imaging findings. Psychol Bull 133: 833-858.
79. Resstel LB, Tavares RF, Lisboa SF, Joca SR, Corrêa FM and Guimarães FS (2009) 5-HT receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156: 181-188.
80. Roffman JL, Marci CD, Glick DM, Dougherty DD and Rauch SL (2005) Neuroimaging and the functional neuroanatomy of psychotherapy. Psychol Med 35: 1385-1398.
81. Russo EB, Burnett A., Hall B. and Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 1037-1043.
82. Saxena S., Brody AL, Maidment KM, Smith EC, Zohrabi N., Katz E., et al. (2004) Cerebral glucose metabolism in obsessive-compulsive hoarding. Am J Psychiatry 161: 1038-1048.
83. Schienle A., Schäfer A., Walter B., Stark R. and Vaitl D. (2005) Brain activation of spider phobics towards disorder-relevant, generally disgust-and fear-inducing pictures. Neurosci Lett 388: 1-6.
84. Schneider F., Weiss U., Kessler C., Muller-Gartner HW, Posse S., Salloum JB, et al. (1999) Subcortical correlates of differential classical conditioning of aversive emotional reactions in social phobia. Biol Psychiatry 45: 863-871.
85. Spindelegger C., Lanzenberger R., Wadsak W., Mien LK, Stein P., Mitterhauser M., et al. (2009) Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders. Mol Psychiatry 14: 1040-1050.
86. Straube T., Mentzel HJ, Glauer M. and Miltner WH (2004) Brain activation to phobia-related words in phobic subjects. Neurosci Lett 372: 204-208.
87. Szeszko PR, Ardekani BA, Ashtari M., Malhotra AK, Robinson DG, Bilder RM, et al. (2005) White matter abnormalities in obsessive-compulsive disorder: a diffusion tensor imaging study. Arch Gen Psychiatry 62: 782-790. (Pubitemid 41002761)
88. Talairach J. and Tournoux P. (1988) Co-planar stereotaxic atlas of the human brain. Stuttgart: Thieme.
89. Thomas A., Baillie GL, Phillips AM, Razdan RK, Ross RA and Pertwee RG (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150: 613-623.
90. Trzesniak C., Araújo D. and Crippa JAS (2008) Magnetic resonance spectroscopy in anxiety disorders. Acta Neuropsychiatrica 20: 56-71.
91. Tung A., Bluhm B. and Mendelson WB (2001) The hypnotic effect of propofol in the medial preoptic area of the rat. Life Sci 69: 855-862.
92. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., et al. (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15: 273-289.
93. Van der Linden G., van Heerden B., Warwick J., Wessels C., van Kradenburg J., Zungu-Dirwayi N., et al. (2000) Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog Neuropsychopharmacol Biol Psychiatry 24: 419-438.
94. Veltman DJ, Tuinebreijer WE, Winkelman D., Lammertsma AA, Witter MP, Dolan RJ, et al. (2004) Neurophysiological correlates of habituation during exposure in spider phobia. Psychiatry Res 132: 149-158.
95. Viveros MP, Marco EM and File SE (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81: 331-342.
96. Vogt BA, Finch DM and Olson CR (1992) Functional heterogeneity in cingulate cortex: the anterior executive and posterior evaluative regions. Cereb Cortex 2: 435-443.
97. Watanabe K., Kayano Y., Matsunaga T., Yamamoto I. and Yoshimura H. (1996) Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull 19: 1109-1111.
98. Wik G., Fredrikson M., Ericson K., Eriksson L., Stone-Elander S. and Greitz T. (1993) A functional cerebral response to frightening visual stimulation. Psychiatry Res 50: 15-24.
99. Zanelati TV, Biojone C., Moreira FA, Guimarães FS and Joca SR (2010) Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 159: 122-128.
100. Zuardi AW (2008) Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 30: 271-280.
101. Zuardi AW and Karniol IG (1981) Transcultural evaluation of a self-evaluation scale of subjective states. J Bras Psiquiatr 131: 403-406.
102. Zuardi AW and Karniol IG (1983) Changes in the conditioned emotional response of rats induced by Δ9-THC, CBD and mixture of the two cannabinoids. Arq Biol Tecnol 26: 391-397.
103. Zuardi AW, Cosme RA, Graeff FG and Guimarães FS (1993 b) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7: 82-88.
104. Zuardi A., Crippa J., Dursun S., Morais S., Vilela J., Sanches R., et al. (2010a) Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol 24: 135-137.
105. Zuardi AW, Crippa JA and Hallak JE (2010 b) Cannabis sativa: the plant that can induce unwanted effects and also treat them. Rev Bras Psiquiatr 32 (Suppl I). S56 - S66.
106. Zuardi AW, Crippa JA, Hallak JE, Moreira FA and Guimarães FS (2006) Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39: 421-429.
107. Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, et al. (2009) Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol 23: 979-983.
108. Zuardi AW, Finkelfarb E., Bueno OFA, Musty RE and Karniol IG (1981) Characteristics of the stimulus produced by the mixture of cannabidiol with D9-tetrahydrocannabinol. Arch Int Pharmacodyn 249: 137-146.
109. Zuardi AW, Guimaraes FS and Moreira AC (1993 a) Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res 26: 213-217.
110. Zuardi AW, Morais SL, Guimarães FS and Mechoulam R. (1995) Antipsychotic effect of cannabidiol. J Clin Psychiatry 56: 485-486.
111. Zuardi AW, Rodrigues JA and Cunha JM (1991) Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 104: 260-264.
112. Zuardi AW, Shirakawa I., Finkelfarb E. and Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 76: 245-250.